文献速递肺栓塞与肺血管病睡眠呼吸障碍

肺动脉高压诊断延迟:澳大利亚与新西兰登记研究解读

Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry.
PubMed 文献 · Respirology · 2020-01-30

基于PHSANZ登记2004-2017年2044例PAH患者,诊断间隔中位1.2年,研究期间未见改善;年龄、CHD-PAH、OSA及外周血管病与诊断间隔≥1年独立相关,较长诊断间隔与5年生存率下降相关。

要点

  • PAH诊断间隔中位1.2年,研究期间未改善。
  • 年龄、CHD-PAH、OSA、外周血管病与诊断延迟相关。
  • 较长诊断间隔与5年生存率下降相关。

核心结论

  • PAH患者存在显著诊断间隔,且研究期间未见改善。
  • 年龄、心血管及呼吸系统合并症与较长诊断时间显著相关。
  • 诊断间隔较长的患者死亡率似乎更高。

研究设计与样本

  • 队列研究,纳入PHSANZ登记2004至2017年诊断为PAH的患者。
  • 共纳入2044例患者,诊断间隔定义为症状出现至诊断性右心导管检查的时间。
  • 采用多变量logistic回归分析诊断延迟相关因素,Kaplan-Meier法和Cox回归比较生存率。

主要发现

  • 诊断时中位年龄58岁(IQR:43-69),女性与男性比例为2.8:1。
  • 多数患者(82%)诊断时NYHA功能分级为III-IV级。
  • 诊断间隔中位1.2年(IQR:0.6-2.7)。
  • 年龄、CHD-PAH、阻塞性睡眠呼吸暂停及外周血管病与诊断间隔≥1年独立相关。
  • 研究期间诊断间隔未见改善;较长诊断间隔与5年生存率下降相关。

临床怎么用

  • 对PAH高危人群应提高早期识别意识,缩短症状至右心导管诊断的时间。
  • 合并心血管或呼吸系统疾病者需警惕诊断延迟风险。
  • 诊断延迟可能影响预后,临床应关注早期转诊与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Early diagnosis of PAH is clinically challenging. Patterns of diagnostic delay in Australian and New Zealand PAH populations have not been explored in large-scale studies. We aimed to evaluate the magnitude, risk factors and survival impact of diagnostic delay in Australian and New Zealand PAH patients. METHODS: A cohort study of PAH patients from the PHSANZ Registry diagnosed from 2004 to 2017 was performed. Diagnostic interval was the time from symptom onset to diagnostic right heart catheterization as recorded in the registry. Factors associated with diagnostic delay were analysed in a multivariate logistic regression model. Survival rates were compared across patients based on the time to diagnosis using Kaplan-Meier method and Cox regression. RESULTS: A total of 2044 patients were included in analysis. At diagnosis, median age was 58 years (IQR: 43-69), female-to-male ratio was 2.8:1 and majority of patients were in NYHA FC III-IV (82%). Median diagnostic interval was 1.2 years (IQR: 0.6-2.7). Age, CHD-PAH, obstructive sleep apnoea and peripheral vascular disease were independently associated with diagnostic interval of ≥1 year. No improvement in diagnostic interval was seen during the study period. Longer diagnostic interval was associated with decreased 5-year survival. CONCLUSION: PAH patients experience significant diagnostic interval, which has not improved despite increased community awareness. Age, cardiovascular and respiratory comorbidities are significantly associated with longer time to diagnosis. Mortality rates appear higher in patients who experience longer diagnostic interval.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Khou V, Anderson JJ, Strange G, et al. Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirology. 2020. PMID: 31997504. doi:10.1111/resp.13768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。